Novo Nordisk: lawsuit claims Pfizer infringes inhaled insulin treatment patent

By Lisa Kerner

Charlotte, N.C., Aug. 2 - Novo Nordisk filed a lawsuit against Pfizer claiming that Pfizer's Exubera infringes patents owned by Novo Nordisk covering inhaled insulin treatment for diabetes.

The lawsuit, filed in U.S. Federal Court in the Southern District of New York, seeks compensatory damages, according to a company news release.

Novo Nordisk said it will also file a motion to prevent Pfizer from continuing its alleged unlawful conduct while the lawsuit is in progress.

Based in Denmark, Novo Nordisk is a health care company specializing in diabetes care and hemostasis management, growth hormone therapy and hormone therapy for women.

Pfizer is a global pharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.